ReCode Therapeutics

OverviewSuggest Edit

ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. Its aim is to create the suppressor tRNA-nanoparticle therapeutics for the correction of genetic mutations. The company focuses on the treatment of cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD).

TypePrivate
Founded2015
HQMenlo Park, CA, US
Websiterecoderx.com

Latest Updates

Employees (est.) (Jul 2021)31(+15%)
Cybersecurity ratingAMore

Key People/Management at ReCode Therapeutics

David J. Lockhart

David J. Lockhart

CEO & President
Julie Eastland

Julie Eastland

Chief Operating Officer and Chief Financial Officer
Vladimir G. Kharitonov

Vladimir G. Kharitonov

Senior Vice President, CMC
Brandon A. Wustman

Brandon A. Wustman

Senior Vice President of R&D
Michael Torres

Michael Torres

Vice President, R&D, Texas Site Head
Show more

ReCode Therapeutics Office Locations

ReCode Therapeutics has offices in Menlo Park and Dallas
Menlo Park, CA, US (HQ)
1455 Adams Dr Suite 1120
Dallas, TX, US
6001 Forest Park Rd
Show all (2)

ReCode Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

ReCode Therapeutics total Funding

$82 m

ReCode Therapeutics latest funding size

$80 m

Time since last funding

a year ago

ReCode Therapeutics investors

ReCode Therapeutics's latest funding round in March 2020 was reported to be $80 m. In total, ReCode Therapeutics has raised $82 m
Show all financial metrics

ReCode Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

ReCode Therapeutics Online and Social Media Presence

Embed Graph

ReCode Therapeutics News and Updates

ReCode Therapeutics to Participate in Upcoming Investor Conferences

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that members of the executive team will be participating in three upcoming virtual investor conferences

ReCode Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:…

ReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial Officer

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO). Eastl…

ReCode Therapeutics Frequently Asked Questions

  • When was ReCode Therapeutics founded?

    ReCode Therapeutics was founded in 2015.

  • Who are ReCode Therapeutics key executives?

    ReCode Therapeutics's key executives are David J. Lockhart, Julie Eastland and Vladimir G. Kharitonov.

  • How many employees does ReCode Therapeutics have?

    ReCode Therapeutics has 31 employees.

  • Who are ReCode Therapeutics competitors?

    Competitors of ReCode Therapeutics include BillionToOne, Synspira and Verona Pharma.

  • Where is ReCode Therapeutics headquarters?

    ReCode Therapeutics headquarters is located at 1455 Adams Dr Suite 1120, Menlo Park.

  • Where are ReCode Therapeutics offices?

    ReCode Therapeutics has offices in Menlo Park and Dallas.

  • How many offices does ReCode Therapeutics have?

    ReCode Therapeutics has 2 offices.